Cargando…

Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy

Great hopes have been placed on human pluripotent stem (hPS) cells for therapy. Tissues or organs derived from hPS cells could be the best solution to cure many different human diseases, especially those who do not respond to standard medication or drugs, such as neurodegenerative diseases, heart fa...

Descripción completa

Detalles Bibliográficos
Autores principales: de Rham, Casimir, Villard, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121106/
https://www.ncbi.nlm.nih.gov/pubmed/25126584
http://dx.doi.org/10.1155/2014/518135
_version_ 1782329174919217152
author de Rham, Casimir
Villard, Jean
author_facet de Rham, Casimir
Villard, Jean
author_sort de Rham, Casimir
collection PubMed
description Great hopes have been placed on human pluripotent stem (hPS) cells for therapy. Tissues or organs derived from hPS cells could be the best solution to cure many different human diseases, especially those who do not respond to standard medication or drugs, such as neurodegenerative diseases, heart failure, or diabetes. The origin of hPS is critical and the idea of creating a bank of well-characterized hPS cells has emerged, like the one that already exists for cord blood. However, the main obstacle in transplantation is the rejection of tissues or organ by the receiver, due to the three main immunological barriers: the human leukocyte antigen (HLA), the ABO blood group, and minor antigens. The problem could be circumvented by using autologous stem cells, like induced pluripotent stem (iPS) cells, derived directly from the patient. But iPS cells have limitations, especially regarding the disease of the recipient and possible difficulties to handle or prepare autologous iPS cells. Finally, reaching standards of good clinical or manufacturing practices could be challenging. That is why well-characterized and universal hPS cells could be a better solution. In this review, we will discuss the interest and the feasibility to establish hPS cells bank, as well as some economics and ethical issues.
format Online
Article
Text
id pubmed-4121106
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41211062014-08-14 Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy de Rham, Casimir Villard, Jean J Immunol Res Review Article Great hopes have been placed on human pluripotent stem (hPS) cells for therapy. Tissues or organs derived from hPS cells could be the best solution to cure many different human diseases, especially those who do not respond to standard medication or drugs, such as neurodegenerative diseases, heart failure, or diabetes. The origin of hPS is critical and the idea of creating a bank of well-characterized hPS cells has emerged, like the one that already exists for cord blood. However, the main obstacle in transplantation is the rejection of tissues or organ by the receiver, due to the three main immunological barriers: the human leukocyte antigen (HLA), the ABO blood group, and minor antigens. The problem could be circumvented by using autologous stem cells, like induced pluripotent stem (iPS) cells, derived directly from the patient. But iPS cells have limitations, especially regarding the disease of the recipient and possible difficulties to handle or prepare autologous iPS cells. Finally, reaching standards of good clinical or manufacturing practices could be challenging. That is why well-characterized and universal hPS cells could be a better solution. In this review, we will discuss the interest and the feasibility to establish hPS cells bank, as well as some economics and ethical issues. Hindawi Publishing Corporation 2014 2014-07-09 /pmc/articles/PMC4121106/ /pubmed/25126584 http://dx.doi.org/10.1155/2014/518135 Text en Copyright © 2014 C. de Rham and J. Villard. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
de Rham, Casimir
Villard, Jean
Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_full Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_fullStr Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_full_unstemmed Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_short Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
title_sort potential and limitation of hla-based banking of human pluripotent stem cells for cell therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121106/
https://www.ncbi.nlm.nih.gov/pubmed/25126584
http://dx.doi.org/10.1155/2014/518135
work_keys_str_mv AT derhamcasimir potentialandlimitationofhlabasedbankingofhumanpluripotentstemcellsforcelltherapy
AT villardjean potentialandlimitationofhlabasedbankingofhumanpluripotentstemcellsforcelltherapy